MELA Sciences Inc.
Sitting pretty: Even in recession-ravaged countries in Southern Europe, beauty sells | Earnings Roundup
Despite a crippling recession which puts it in the epicenter of the European debt crisis, it still seems Southern Europe puts a premium on not just the beauty of its land, but those of its people as well.
On Wednesday Allergan (NYSE:AGN) reported stronger than expected sales of its breast implants, Botox and other aesthetic devices in places like Spain, where the unemployment rate tips 24% – more than 3 times that of the U.S.
MassDevice.com +3 | The top 3 med-tech stories for March 22, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Mela Sciences’ Joe Gulfo on returning to the market in the shadow of the medical device tax
Mela Sciences (NSDQ:MELA) CEO Joe Gulfo tells MassDevice that he feels like a kid in a candy store as he takes the company back to market – and not even the ever-looming burden of the medical device tax can dampen his enthusiasm.
Analyst: CRM market “bad as it’s ever been” | Wall Street Beat
The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
Mela Sciences narrows losses ahead of 1st MelaFind revenues | Earnings Roundup
Mela Sciences (NSDQ:MELA) narrowed losses and met Wall Street’s expectations with its 4th-quarter results.
The Irvington, N.Y.-based melanoma detection device maker reported losses of $4.5 million, or 21¢ per share, in the 3 months ended Dec. 31, 2011. That compares with losses of $5.3 million, or 21¢ per share, during the same period in 2010.
GE Healthcare announces layoffs in Vermont | MassDevice.com On Call
Updated March 7, 2012, at 1:30 p.m. with comments from GE Healthcare.
MASSDEVICE ON CALL — GE Healthcare (NYSE: GE) announced another round of layoffs at its South Burlington, Vt., facility, a move it said is a result of declining demand for health care IT and performance solutions businesses.
The move is the "subsequent action" of layoffs numbering around 50 workers at the same facility last month, GE spokesman Corey Miller told MassDevice.
J&J’s cred fades for 1st time in 13 years | MassDevice.com On Call
MASSDEVICE ON CALL — Incoming Johnson & Johnson (NYSE:JNJ) CEO Alex Gorsky will have a full plate when he takes the corner office in April.
Amid ongoing recalls and related lawsuits, Gorsky has his work cut out for him in restoring consumer faith in health care giant.
MassDevice.com +3 | The top 3 med-tech stories for January 24, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Mela Sciences prepares to launch MelaFind with new manufacturing deal | Deals Roundup
Mela Sciences (NSDQ:MELA) announced an expanded 3-year manufacturing contract with long-time supplier Askion GmbH for production of the MelaFind devices.
MelaFind, the company’s flagship product, is a handheld, non-invasive melanoma detection and identification system designed to help a physician decide whether or not to biopsy a suspect patch of skin.
Mela Sciences announces $15M public offering | Funding Roundup
Mela Sciences (NSDQ:MELA) priced a public offering of 5 million shares of common stock at $3.25 per share, hoping to raise up to $14.9 million.
President & CEO Joseph Gulfo and director Robert Coradini agreed to purchase 43,000 shares at the Dec. 15 closing price of $3.97 per share.
